BD (Becton, Dickinson and Company), a Franklin Lakes-based global medical technology company, today announced a transition in its executive leadership alongside strong preliminary revenue results for the close of its fiscal year.
Chris DelOrefice, executive vice president and chief financial officer (CFO), will depart the company on Dec. 5, to pursue a new professional opportunity. The company has initiated a search for a permanent successor.
Vitor Roque, senior vice president of finance, business units and corporate financial planning and analysis, has been named interim CFO, effective upon DelOrefice’s departure. Roque will work with DelOrefice to ensure a smooth transition.
“Chris has been an important part of our Executive Leadership Team over the past four years as we delivered on our BD 2025 strategy,” Tom Polen, chairman, CEO and president of BD said. He added that Roque’s two decades of experience in various finance leadership roles across BD’s regions and business segments position him well for the interim role.
Preliminary fiscal 2025 revenue results
In conjunction with the transition announcement, BD released selected unaudited preliminary results for the fourth quarter and full year fiscal 2025, which ended Sept. 30:
- Full Year Preliminary Revenue is approximately $21.8 billion. This represents an estimated increase of approximately 8.2% on a reported basis and 2.9% on an organic basis.
- Fourth Quarter Preliminary Revenue is approximately $5.9 billion, representing estimated organic growth of 3.9%.
Polen noted that while the company navigated a “dynamic macro environment” with greater-than-anticipated impacts in areas like Pharmaceutical Systems vaccines and Biosciences research, BD still delivered “strong growth” across multiple segments, including BD Interventional, Advanced Patient Monitoring, and Medication Delivery Solutions.
The company expects to deliver full year fiscal 2025 adjusted diluted earnings per share (EPS) at or above the midpoint of its previously issued guidance.
Polen indicated that the company is continuing to execute its strategy and taking “further action to unlock value,” including investments aimed at driving growth and continued margin momentum. Further details on the company’s “New BD strategy” and expectations for fiscal 2026 are slated for the upcoming earnings call.
BD will host an audio webcast to discuss its full financial results for the fourth quarter and full year fiscal 2025 on Nov. 6, at 8 a.m. (ET).
